Private Capital Advisors Inc. lessened its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 3.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 42,936 shares of the medical research company’s stock after selling 1,360 shares during the period. Thermo Fisher Scientific comprises 2.4% of Private Capital Advisors Inc.’s investment portfolio, making the stock its 8th largest holding. Private Capital Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $7,491,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Waldron LP increased its holdings in shares of Thermo Fisher Scientific by 48.1% in the 1st quarter. Waldron LP now owns 4,455 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 1,447 shares during the period. Foster & Motley Inc. increased its holdings in shares of Thermo Fisher Scientific by 5.1% in the 1st quarter. Foster & Motley Inc. now owns 21,945 shares of the medical research company’s stock valued at $3,371,000 after purchasing an additional 1,074 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Thermo Fisher Scientific by 52.4% in the 1st quarter. Fisher Asset Management LLC now owns 2,602 shares of the medical research company’s stock valued at $400,000 after purchasing an additional 895 shares during the period. BTR Capital Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 5.0% in the 1st quarter. BTR Capital Management Inc. now owns 69,651 shares of the medical research company’s stock valued at $10,698,000 after purchasing an additional 3,324 shares during the period. Finally, Profund Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 10.8% in the 1st quarter. Profund Advisors LLC now owns 15,864 shares of the medical research company’s stock valued at $2,437,000 after purchasing an additional 1,543 shares during the period. Hedge funds and other institutional investors own 83.52% of the company’s stock.

In related news, Director C Martin Harris sold 360 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total value of $65,149.20. Following the sale, the director now owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jim P. Manzi sold 11,318 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the completion of the sale, the director now directly owns 38,757 shares in the company, valued at approximately $6,702,635.58. The disclosure for this sale can be found here. In the last three months, insiders sold 18,844 shares of company stock worth $3,300,421. 0.49% of the stock is owned by insiders.

Shares of Thermo Fisher Scientific Inc (TMO) traded down 0.61% during midday trading on Monday, hitting $186.00. The company had a trading volume of 1,404,832 shares. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $188.76. The firm has a market capitalization of $72.56 billion, a P/E ratio of 32.40 and a beta of 1.05. The firm’s 50-day moving average is $177.39 and its 200-day moving average is $168.43.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The business had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. During the same quarter last year, the firm earned $2.03 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 10.2% compared to the same quarter last year. On average, analysts predict that Thermo Fisher Scientific Inc will post $9.35 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.

TRADEMARK VIOLATION WARNING: “Thermo Fisher Scientific Inc (TMO) Holdings Cut by Private Capital Advisors Inc.” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/04/thermo-fisher-scientific-inc-tmo-holdings-cut-by-private-capital-advisors-inc.html.

A number of equities analysts have recently weighed in on TMO shares. Bank of America Corporation reiterated a “buy” rating and issued a $210.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a report on Friday, July 21st. Zacks Investment Research downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Cantor Fitzgerald started coverage on Thermo Fisher Scientific in a report on Thursday, May 18th. They issued an “overweight” rating and a $194.00 target price on the stock. BidaskClub downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Finally, Cowen and Company reiterated a “buy” rating and issued a $200.00 target price on shares of Thermo Fisher Scientific in a report on Friday. One research analyst has rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $189.50.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.